Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ITWJ..Integrated Software Development Sells to Localization Service Company
NWBT...prolongs life
MTNA,news LOS ANGELES, CA--(MARKET WIRE)--Feb 23, 2006 -- Renowned bridge engineering expert, Dr. Brent Phares, PE, Marketing Director for Material Technologies, Inc.'s (OTC BB:MTNA.OB - News) (MATECH) will speak at the 23rd Annual International Bridge Conference, June 12-14, in Pittsburgh, Pennsylvania. Dr. Phares, an expert in bridge testing, evaluation, design and construction, will make a presentation and lead a discussion on the accuracy, cost and application of MATECH's patented Electrochemical Fatigue Sensor (EFS(TM)), an innovative nondestructive crack detection system.
For a good day try MTNA....Johnsbus
NWBT...Overview
Northwest Biotherapeutics (NWBT) is a biotechnology company focused on the clinical development of autologous immunotherapy products for cancer. Our technology platform, DCVax®, uses a patient’s own dendritic cells, the starter engine of the immune system, which are loaded with tumor proteins or antigens. Injection of these cells back into the patient initiates a potent immune response against cancer cells, resulting in delayed time to progression and prolonged survival. Our two lead product candidates, DCVax®-Prostate and DCVax®-Brain are entering FDA-allowed late stage clinical trials from which licensure is possible. Other, related products in our pipeline are ready to enter Phase I clinical trials. The advantage of our DCVax® platform is derived from:
the high quality and purity of our DCVax® product candidates;
our unique therapeutic approach in which immunotherapy is positioned as an adjuvant treatment in patients with low tumor burden;
our proprietary, efficient, and low cost method of product manufacturing.
Business Strategy
NWBT’s mission is to become a leading developer and supplier of cost-effective, non-toxic immunotherapies for primary or adjuvant treatment of cancers. We will focus on those product candidates that allow rapid commercialization to generate return for our shareholders, and that provide the resources required for continued development of potential additional products with longer lead times. We will continue to develop partnerships for commercialization, and marketing of our products with the goal of rapid market penetration without diluting our focus on clinical product development.
Initial Product Candidates
Our lead product candidates are immunotherapy treatments that safely generate and enhance immune system responses to effectively treat multiple types of cancer.
DCVax®-Brain: We anticipate enrolling patients with newly diagnosed Glioblastoma multiforme in the summer of 2005 in a 143 patient, FDA cleared Phase II clinical trial in 12-15 clinical centers in the United States.
DCVax®-Prostate: We anticipate enrolling patients with non-metastatic, hormone independent prostate cancer in Q4 of 2005 in a 612 patient, FDA cleared Phase III clinical trial in 40 to 50 clinical centers in the United States.
NWBT..Northwest Biotherapeautics Inc. ,Brain Cancer Patients Living Longer and Doing Better After Personalized Vaccine Therapy
Even if the run retraces somewhat NWBT will prove itself a real winner in the near future.
I looked everywhere for info and realized the potential is greater for blockbuster PR`S down the road. Johnsbus
This is BIG..... REALLY BIG.
I have 35 trades for 29K shares...people adding ????
IGTG...QTR rev growth 170%(yoy),o/s 12M news today Johnsbus
on board, @.23 (product is three yrs to late for my brother in law) personal interest here. GLTA Johnsbus
NWBT..brain tumor study prolongs life
Just two weeks ago I read in Business Week (or was it on CNBC????) that security analysts are totally stumped why this sector has not taken off. Good...that means i`m in on the ground floor. Johnsbus
I was lucky to buy at .31 after two days of DD and watching the race but also agree the company needs someone that can write. RFID everywhere. Johnsbus (has RFID tires etc.)
AIDO..RFID tags on bulls,bears and pigs..rental car tires and boxes for tracking. cloths..... EVERYTHING.Johnsbus
AIDO, going strong RFID tags in NASCAR tires
For IBZT a 1 for 100,000 R/S seems possible...WOOOOOOW
mPhase names nano researcher chief scientist
Feb. 15, 2006 – Little Falls, N.J.-based mPhase Technologies Inc. (OTC: XDSL) has named its lead nanotechnology researcher Victor Lifton to the position of chief scientist. He will have a larger responsibility for the company's emphasis on "small" technology, including its "smart" nanostructured battery and ultra-sensitive uncooled magnetometer.
Lifton joined mPhase Technologies in June, 2004 from Kulite Semiconductor Products Inc., where he was manager of semiconductor processing. Previously he was with Lucent Technologies/Bell Labs, where he was a member of technical staff in the MEMS Fabrication Research Lab
AXNP...early momo "luck is being ready when the opportunity presents itself".
MeridCom inc. is the holder of a GSA FSS Contract (GS 35F 0500P), offering secure internet access to government agencies and contractors
MTNA....MATECH'S Innovative Bridge Crack Detection Technology Meets Strict Government Requirements
EVSC...Endovasc Receives Notice of Allowance for U.S. Patent Protecting Its Muscle Mass Technology
EVSC...Endovasc Receives Notice of Allowance for U.S. Patent Protecting Its Muscle Mass Technology
2.15.06 R/S 1 for 3000 new symbol, ITRJ (eom)
mPhase is XDSL
mPhase Technologies Demonstrates Delivery of IPTV Over Switched Ethernet Connection at NORWECOM 2006
Wednesday February 15, 9:03 am ET
Cost-Effective Interactive TV Solution Serves to Highlight Quality of Service Control
ST. PETERSBURG, Russia--(BUSINESS WIRE)--Feb. 15, 2006--mPhase Technologies, a pioneer developer of technology for delivering television over telephone networks, this week is demonstrating how telecommunications providers can now cost-effectively market TV programs as part of a switched Ethernet multi-service offer encompassing VoIP, high speed Internet data and streaming video.
I think RS has a bad rap. If the company has good legs to stand on the benefits could be very rewarding. If it`s a dog... well what can i say?
It would be nice if the PR team would throw is a bone or two.GLA-Johnsbus
MTNA...bridge crack detection,DOT loves it,federal $,dip today. Johnsbus
I almost forgot i had PLKC. i`m down so far the crawl will be long but i`m in. GLA
Just noticed you opened shop...nothing to add at this time except my certs have been gathering dust for years. They will make money ...later than sooner.GL Johnsbus
MTNA..bridge failure detection news eom
MTNA..news-Bridge crack detection sensor.eom
LOS ANGELES, CA--(MARKET WIRE)--Feb 10, 2006 -- Material Technologies, Inc. (OTC BB:MTNA.OB - News) ("MATECH") demonstrated its Electrochemical Fatigue Sensor (EFS(TM)) technology, a patented crack detection system, to state departments of transportation and other transportation agencies on steel bridges located across the nation with exciting results over the last year.
XDSL,nano battery partnered w/ Lucent /Bell Labs news. JB
LITTLE FALLS, N.J. & MURRAY HILL, N.J.--(BUSINESS WIRE)--Feb. 9, 2006--mPhase Technologies (OTCBB:XDSL - News) and Lucent Technologies Bell Labs (NYSE:LU - News) today reported that their jointly developed nano-based "smart" battery prototype has proven it can store and convert energy on demand. This practical confirmation of the theory behind the technology is a major milestone in the product development process
CALIMESA, Calif., Feb. 9 /PRNewswire-FirstCall/ -- Ingen Technologies, Inc. (OTC: IGTG - News), a medical device manufacturer of OxyAlert(TM), OxyView(TM), and Secure Balance(TM), announces that the company's Secure Balance(TM) products will be televised on major news stations to millions of consumers throughout the United States and abroad
Qtrly Revenue Growth (yoy): 1849.30% for ISCR
ISCR..instaCare Corp. Announces Agreements with Two Major Pharmaceutical Companies to Supply Diabetic Monitoring Products Valued at $12 Million Per Year
ISCR...
ISCR..12Mil. yearly med.contract
ISCR..bought between the bid/ask.75 goin north